Pharmaceutical composition for treating glioma

A technology for glioma and composition, applied in the field of medicine, can solve the problems of small selection of drugs, lack of effective drugs, etc., and achieve the effect of reducing side effects

Inactive Publication Date: 2016-07-13
WENZHOU TONGYI BIOMEDICAL TECH CO LTD
View PDF1 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

But we found that for many glioma diseases, not only is there a lack of effective drugs, but also the drug options are small

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition for treating glioma
  • Pharmaceutical composition for treating glioma
  • Pharmaceutical composition for treating glioma

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0043] Embodiment 1: A kind of pharmaceutical composition for treating glioma, according to percentage by weight, it is made up of 55% component A, 23% component B, 10% component C and 12% component D, group Part A is a diterpene compound (I) having the following structural formula:

[0044]

[0045] Component B is withanolide compound (II) having the following structural formula:

[0046]

[0047] Component C is a triterpenoid saponin compound echinosideA, structural formula (Ⅲ):

[0048]

[0049] Component D is a flavonoid compound (IV) having the following structural formula:

[0050]

[0051] Wherein, the separation preparation and structural confirmation of the diterpene compound (I) in component A are as follows:

[0052] Main materials, sources of reagents and types of instruments:

[0053] Ethanol, petroleum ether, ethyl acetate, n-butanol, and dichloromethane were of analytical grade, purchased from Shanghai Lingfeng Chemical Reagent Co., Ltd. Methanol,...

Embodiment 2

[0070] Embodiment 2: the pharmaceutical composition pharmacological action test in embodiment 1

[0071] 1. Materials and Instruments

[0072] In this experiment, the human brain malignant glioblastoma U251 cell line was purchased from the American Type Culture Collection. DMEM high-glucose medium was purchased from Hyclone Company of the United States; sodium chloride, sodium hydroxide, potassium chloride, oxygen chloride, sodium hydroxide, disodium hydrogen phosphate, sodium dihydrogen phosphate, potassium dihydrogen phosphate, and methanol were purchased from Nanjing chemical plant. Glycine, Tris, Tween20, and dimethyl sulfoxide (DMEM) were purchased from Sigma, USA; Aimexin-V / PI cell death kit was purchased from Invitrogen, USA; cell lysate, 0.25% trypsin, CellCountingKit-8 kit , penicillin, streptomycin, Hoechst33258, nuclear dye DAPI, PMSF, Westernblot gel preparation kit, nuclear protein extraction kit, Coomassie brilliant blue staining solution, standard protein, 5X ...

Embodiment 3

[0096] A pharmaceutical composition for treating glioma, comprising a therapeutically effective amount of the pharmaceutical composition of Example 1 above and a pharmaceutically acceptable carrier. The pharmaceutically acceptable carrier is selected from one or more of the following: lactose, sucrose, gelatin, agar, pectin, gum arabic, magnesium stearate, stearic acid, lower alkyl ethers of cellulose , Corn Starch, Potato Starch, Gums, Fatty Acids, Glyceryl Monostearate. The daily effective dosage of the pharmaceutical composition (excluding pharmaceutically acceptable carrier) in the above-mentioned Example 1 is 0.001-0.006g / kg human body, and it can be made into the medicine with corresponding content according to the need, and taken according to the doctor's advice.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
diameteraaaaaaaaaa
degree of unsaturationaaaaaaaaaa
degree of unsaturationaaaaaaaaaa
Login to view more

Abstract

The invention belongs to the technical field of medicine and particularly relates to a pharmaceutical composition for treating glioma.The pharmaceutical composition comprises a component A, a component B, a component C and a component D, wherein the component A is diterpenoids (I) extracted from callicarpa nudiflora, the component B is withanolides (II) extracted from the dried whole herb of asiatic plantain, the component C is triterpenoid saponins echinoside A purchased from the market, and the component D is flavonoids (IV) extracted from the overground part of vervain.In-vitro experiment prove that the pharmaceutical composition can inhibit the human brain malignant glioblastoma U251 cells by inhibiting cell proliferation and inducing cell apoptosis and can be developed into medicine for treating the glioma.

Description

technical field [0001] The invention belongs to the technical field of medicines, and in particular relates to a pharmaceutical composition for treating glioma. Background technique [0002] Glioma, also known as glioma for short, is the most common primary central nervous system tumor, accounting for about half of all primary intracranial tumors. In a broad sense, it refers to all neuroepithelial-derived tumors. In a narrow sense, it refers to tumors derived from various types of glial cells. According to the classification scheme of the World Health Organization (WHO) in 1999, it is divided into astrocytoma, oligobranchoma, ependymoma, mixed glioma, choroid plexus tumor, neuroepithelial tumor of uncertain origin, and neuroepithelial tumor. Neuronal and neuronal glioma, pineal parenchymal tumor, embryonal tumor, neuroblastoma tumor. [0003] At present, the main treatment for glioma is surgery, but the risk of surgery is extremely high. At present, hormone therapy can be...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/7048A61P35/00A61K31/352A61K31/585A61K31/357
CPCA61K31/352A61K31/357A61K31/585A61K31/7048A61K2300/00
Inventor 王赛波
Owner WENZHOU TONGYI BIOMEDICAL TECH CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap